ArticleiScience2022

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.

Oana Hangiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.